Inflammation in retinal vein occlusion

International Journal of Inflammation

Volumn 2013, Issue , 2013, Pages

  Deobhakta, Avnish ^a   Chang, Louis K ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; RANIBIZUMAB; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN;

ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; DRUG DOSE COMPARISON; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; LASER COAGULATION; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; REVIEW; RISK FACTOR; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT;

EID: 84877245304     PISSN: 20908040     EISSN: 20420099     Source Type: Journal    
DOI: 10.1155/2013/438412     Document Type: Review

References (62)

1. Shahid H., Hossain P., Amoaku W. M., The management of retinal vein occlusion: is interventional ophthalmology the way forward? British Journal of Ophthalmology 2006 90 5 627 639 2-s2.0-33646259686 10.1136/bjo.2005.068668
2. Hayreh S. S., Zimmerman M. B., Podhajsky P., Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. American Journal of Ophthalmology 1994 117 4 429 441 2-s2.0-0028204368 (Pubitemid 24115701)
3. Koizumi H., Ferrara D. C., Bruè C., Spaide R. F., Central retinal vein occlusion case-control study. American Journal of Ophthalmology 2007 144 6 858 863 2-s2.0-36248933683 10.1016/j.ajo.2007.07.036 (Pubitemid 350130236)
4. The Eye Disease Case-Control Study Group, Risk factors for central retinal vein occlusion the eye disease case-control study group. Archives of Ophthalmology 1996 114 5 545 554 2-s2.0-3142624510
5. Shahsuvaryan M. L., Therapeutic potential of intravitreal pharmaco-therapy in retinal vein occlusion. Indian Journal of Ophthalmology 2012 5 6 759 770
6. Sperduto R. D., Hiller R., Chew E., Seigel D., Blair N., Burton T. C., Farber M. D., Gragoudas E. S., Haller J., Seddon J. M., Yannuzzi L. A., Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study. Ophthalmology 1998 105 5 765 771 2-s2.0-13144294086 10.1016/S0161-6420(98)95012- 6
7. Jain S., Hurst J. R., Thompson J. R., Eke T., UK national survey of current practice and experience of intravitreal triamcinolone acetonide. Eye 2009 23 5 1164 1167 2-s2.0-65949115709 10.1038/eye.2008.185
8. Ladjimi A., Zeghidi H., Ben Yahia S., Zaouali S., Jenzri S., Messaoud R., Attia S., Khairallah M., Intravitreal injection of triamcinolone acetonide for the treatment of macular edema. Journal Francais d'Ophtalmologie 2005 28 7 749 757 2-s2.0-26944459212 (Pubitemid 41480591)
9. The Branch Vein Occlusion Study Group, Argon laser photocoagulation for macular edema in branch vein occlusion. American Journal of Ophthalmology 1984 98 3 271 282
10. Campochiaro P. A., Heier J. S., Feiner L., Gray S., Saroj N., Rundle A. C., Murahashi W. Y., Rubio R. G., Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010 117 6 1102.e1 1112.e1 2-s2.0-77952891051 10.1016/j.ophtha.2010.02.021
11. McGimpsey S. J., Woodside J. V., Cardwell C., Cahill M., Chakravarthy U., Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: a meta-analysis. Ophthalmology 2009 116 9 1778 1787 2-s2.0-69349090928 10.1016/j.ophtha.2009.02.033
12. Blice J. B., Brown G. C., Spaide R. F.,. Retinal vascular occlusive disease. Diseases of the Retina and the Vitreous 1999 Philadelphia, Pa, USA WB Saunders 109 127
13. Ross R., Atherosclerosis-an inflammatory disease. New England Journal of Medicine 1999 340 115 126
14. Stary H. C., Chandler A. B., Glagov S., Guyton J. R., Insull W., Rosenfeld M. E., Schaffer S. A., Schwartz C. J., Wagner W. D., Wissler R. W., A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Circulation 1994 89 5 2462 2478 2-s2.0-0028289443 (Pubitemid 24142837)
15. Cheung N., Klein R., Jie J. W., Cotch M. F., Islam A. F. M., Klein B. E. K., Cushman M., Tien Y. W., Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Investigative Ophthalmology and Visual Science 2008 49 10 4297 4302 2-s2.0-53449090577 10.1167/iovs.08-1826
16. Steinbrugger I., Haas A., Maier R., Renner W., Mayer M., Werner C., Wedrich A., El-Shabrawi Y., Schmut O., Weger M., Analysis of inflammation- and atherosclerosis-related gene polymorphisms in branch retinal vein occlusion. Molecular Vision 2009 15 609 618 2-s2.0-65249147663
17. Maier R., Steinbrugger I., Haas A., Selimovic M., Renner W., El-Shabrawi Y., Werner C., Wedrich A., Schmut O., Weger M., Role of inflammation-related gene polymorphisms in patients with central retinal vein occlusion. Ophthalmology 2011 118 6 1125 1129
18. Song Y.-J., Cho K.-I., Kim S.-M., Jang H.-D., Park J.-M., Kim S.-S., Kim D.-J., Lee H.-G., Kim T.-I., The predictive value of retinal vascular findings for carotid artery atherosclerosis: are further recommendations with regard to carotid atherosclerosis screening needed? Heart and Vessels 2012 10.1007/s00380-012-0258-1
19. Aydin Kaderli A., Kaderli B., Gullulu S., Avci R., Impaired aortic stiffness and pulse wave velocity in patients with branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology 2010 248 3 369 374 2-s2.0-77949275748 10.1007/s00417-009-1271-7
20. Green W. R., Chan C. C., Hutchins G. M., Terry J. M., Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Retina 1981 1 1 27 55 2-s2.0-0019768239 (Pubitemid 12160821)
21. Neumann F. J., Ott I., Marx N., Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arteriosclerosis, Thrombosis, and Vascular Biology 1997 17 3399 3405 (Pubitemid 28028548)
22. van der Poll T., Buller H. R., Ten Cate H., Wortel C. H., Bauer K. A., van Deventer S. J. H., Hack C. E., Sauerwein H. P., Rosenberg R. D., Ten Cate J. W., Activation of coagulation after administration of tumor necrosis factor to normal subjects. New England Journal of Medicine 1990 322 23 1622 1627 (Pubitemid 20171585)
23. Ulfhammer E., Larsson P., Karlsson L., Hrafnkelsdóttir T., Bokarewa M., Tarkowski A., Jern S., TNF mediated suppression of tissue type plasminogen activator expression in vascular endothelial cells is NF- B- and p38 MAPK-dependent. Journal of Thrombosis and Haemostasis 2006 4 8 1781 1789 2-s2.0-33746629771 10.1111/j.1538-7836.2006.02035.x (Pubitemid 44144806)
24. Boushey C. J., Beresford S. A. A., Omenn G. S., Motulsky A. G., A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. Journal of the American Medical Association 1995 274 13 1049 1057 2-s2.0-0029066299
25. Chambers J. C., McGregor A., Jean-Marie J., Kooner J. S., Acute hyperhomocysteinaemia and endothelial dysfunction. The Lancet 1998 351 9095 36 37 2-s2.0-0002313552
26. Hajjar K. A., Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. Journal of Clinical Investigation 1993 91 6 2873 2879 2-s2.0-0027288252 (Pubitemid 23182548)
27. Rodgers G. M., Conn M. T., Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990 75 4 895 901 2-s2.0-0025190042 (Pubitemid 20067188)
28. Weger M., Stanger O., Deutschmann H., Temmel W., Renner W., Schmut O., Semmelrock J., Haas A., Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology 2002 240 4 286 290 2-s2.0-0036938568 10.1007/s00417-002-0431-9 (Pubitemid 36075597)
29. Cahill M., Karabatzaki M., Meleady R., Refsum H., Ueland P., Shields D., Mooney D., Graham I., Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. British Journal of Ophthalmology 2000 84 2 154 157 2-s2.0-0034100878 10.1136/bjo.84.2.154 (Pubitemid 30251658)
30. Kesler A., Shalev V., Rogowski O., Shimron O., Shainberg B., Sela B. A., Shapira I., Salomon O., Berliner S., Comparative analysis of homocysteine concentrations in patients with retinal vein occlusion versus thrombotic and atherosclerotic disorders. Blood Coagulation and Fibrinolysis 2008 19 4 259 262 2-s2.0-43449116387 10.1097/MBC.0b013e3282f2b60e (Pubitemid 351670408)
31. Noma H., Funatsu H., Mimura T., Harino S., Eguchi S., Hori S., Pigment epithelium-derived factor and vascular endothelial growth factor in branch retinal vein occlusion with macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology 2010 248 11 1559 1565 2-s2.0-77957659527 10.1007/s00417-010-1486-7
32. Noma H., Funatsu H., Mimura T., Eguchi S., Shimada K., Inflammatory factors in major and macular branch retinal vein occlusion. Ophthalmologica 2012 227 3 146 152
33. Yoshimura T., Sonoda K. H., Sugahara M., Mochizuki Y., Enaida H., Oshima Y., Ueno A., Hata Y., Yoshida H., Ishibashi T., Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS ONE 2009 4 12 2-s2.0-77949537099 10.1371/journal.pone.0008158 e8158
34. Noma H., Funatsu H., Mimura T., Eguchi S., Vitreous inflammatory factors and serous retinal detachment in central retinal vein occlusion: a case control series. Journal of Inflammation 2011 8, article 38 10.1186/1476-9255-8-38
35. Noma H., Funatsu H., Mimura T., Tatsugawa M., Shimada K., Eguchi S., Vitreous inflammatory factors and serous macular detachment in branch retinal vein occlusion. Retina 2012 32 1 86 91 10.1097/IAE.0b013e31821801de
36. Lim J. W., Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion. Ophthalmologica 2011 225 3 150 154 2-s2.0-78649763817 10.1159/000322364
37. Adamis A. P., Is diabetic retinopathy an inflammatory disease? British Journal of Ophthalmology 2002 86 4 363 365 2-s2.0-0036216417 10.1136/bjo.86.4.363 (Pubitemid 34293277)
38. Nakao S., Arima M., Ishikawa K., Kohno R., Kawahara S., Miyazaki M., Enaida H., Hafezi-Moghadam A., Kono T., Ishibashi T., Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis. Investigative Ophthalmology & Visual Science 2012 53 7 4323 4328
39. Ossewaarde-Van Norel A., Rothova A., Clinical review: update on treatment of inflammatory macular edema. Ocular Immunology and Inflammation 2011 19 1 75 83 2-s2.0-79952824489 10.3109/09273948.2010.509530
40. Kaur C., Foulds W. S., Ling E. A., Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Progress in Retinal and Eye Research 2008 27 6 622 647 2-s2.0-55849146641 10.1016/j.preteyeres.2008.09.003
41. Jonas J. B., Intraocular availability of triamcinolone acetonide after intravitreal injection. American Journal of Ophthalmology 2004 137 3 560 562 2-s2.0-1542297321 10.1016/j.ajo.2003.08.012 (Pubitemid 38328652)
42. Jonas J. B., Concentration of intravitreally injected triamcinolone acetonide in aqueous humour. British Journal of Ophthalmology 2002 86 9 1066 2-s2.0-0036723967 10.1136/bjo.86.9.1066
43. Ip M., Kahana A., Altaweel M., Treatment of central retinal vein occlusion with triamcinolone acetonide: an optical coherence tomography study. Seminars in Ophthalmology 2003 18 2 67 73 2-s2.0-0043239239 10.1076/soph.18.2. 67.15860 (Pubitemid 37108395)
44. Jonas J. B., Akkoyun I., Kamppeter B., Kreissig I., Degenring R. F., Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. European Journal of Ophthalmology 2005 15 6 751 758 2-s2.0-29244447509 (Pubitemid 43074702)
45. Ip M. S., Scott I. U., vanVeldhuisen P. C., Oden N. L., Blodi B. A., Fisher M., Singerman L. J., Tolentino M., Chan C. K., Gonzalez V. H., A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Archives of Ophthalmology 2009 127 9 1101 1114 2-s2.0-70349243148 10.1001/archophthalmol.2009.234
46. Scott I. U., Ip M. S., vanVeldhuisen P. C., Oden N. L., Blodi B. A., Fisher M., Chan C. K., Gonzalez V. H., Singerman L. J., Tolentino M., A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 6. Archives of Ophthalmology 2009 127 9 1115 1128 2-s2.0-70349247768 10.1001/archophthalmol.2009.233
47. Haller J. A., Bandello F., Belfort R., Blumenkranz M. S., Gillies M., Heier J., Loewenstein A., Yoon Y. H., Jacques M. L., Jiao J., Li X. Y., Whitcup S. M., Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010 117 6 1134 1146 2-s2.0-77952882990 10.1016/j.ophtha.2010.03.032
48. Yeh W. S., Haller J. A., Lanzetta P., Kuppermann B. D., Wong T. Y., Mitchell P., Whitcup S. M., Kowalski J. W., Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 2012 119 6 1190 1198
49. Reibaldi M., Russo A., Zagari M., Toro M., De Grande V., Cifalinò V., Rametta S., Faro S., Resolution of persistent cystoid macular edema due to central retinal vein occlusion in a vitrectomized eye following intravitreal implant of dexamethasone 0.7 mg. Case Reports in Ophthalmology 2012 3 1 30 34 10.1159/000336273
50. Kiss S., Moving beyond laser in treatment of DME, BRVO. Retina Today 2012 48 50
51. Campochiaro P. A., Heier J. S., Feiner L., Gray S., Saroj N., Rundle A. C., Murahashi W. Y., Rubio R. G., Ranibizumab for macular edema following branch retinal vein occlusion six-month primary end point results of a phase III study. Ophthalmology 2010 117 6 1102 1112 2-s2.0-77952891051 10.1016/j.ophtha.2010.02.021
52. Brown D. M., Campochiaro P. A., Singh R. P., Li Z., Gray S., Saroj N., Rundle A. C., Rubio R. G., Murahashi W. Y., Ranibizumab for macular edema following central retinal vein occlusion six-month primary end point results of a phase III study. Ophthalmology 2010 117 6 1124 1133 2-s2.0-77952889477 10.1016/j.ophtha.2010.02.022
53. Campochiaro P. A., Brown D. M., Awh C. C., Lee S. Y., Gray S., Saroj N., Murahashi W. Y., Rubio R. G., Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011 118 10 2041 2049 10.1016/j.ophtha.2011.02.038
54. Brown D. M., Campochiaro P. A., Bhisitkul R. B., Ho A. C., Gray S., Saroj N., Adamis A. P., Rubio R. G., Murahashi W. Y., Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011 118 8 1594 1602 2-s2.0-79958817527 10.1016/j.ophtha.2011.02.022
55. Chung E. J., Hong Y. T., Lee S. C., Kwon O. W., Koh H. J., Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology 2008 246 9 1241 1247 2-s2.0-48449106803 10.1007/s00417-008-0866-8
56. Prager F., Michels S., Kriechbaum K., Georgopoulos M., Funk M., Geitzenauer W., Polak K., Schmidt-Erfurth U., Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. British Journal of Ophthalmology 2009 93 4 452 456 2-s2.0-64849111444 10.1136/bjo.2008.141085
57. Kondo M., Kondo N., Ito Y., Kachi S., Kikuchi M., Yasuma T. R., Ota I., Miyake K., Terasaki H., Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. Retina 2009 29 9 1242 1248 2-s2.0-70350149839 10.1097/IAE.0b013e3181aa8e20
58. Wu L., Arevalo J. F., Berrocal M. H., Maia M., Roca J. A., Morales-Cantón V., Alezzandrini A. A., Díaz-Llopis M. J., Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American collaborative retina study group at 24 months. Retina 2009 29 10 1396 1403 2-s2.0-73349118494 10.1097/IAE.0b013e3181bcef53
59. Ach T., Hoeh A. E., Schaal K. B., Scheuerle A. F., Dithmar S., Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology 2010 248 2 155 159 2-s2.0-77949273912 10.1007/s00417-009-1167-6
60. Epstein D. L. J., Algvere P. V., von Wendt G., Seregard S., Kvanta A., Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 2012 119 6 1184 1189 10.1016/j.ophtha.2012.01.022
61. Wang H. Y., Li X., Wang Y. S., Zhang Z. F., Li M. H., Su X. N., Zhu J. T., Intravitreal injection of bevacizumab alone or with triamcinolone acetonide for treatment of macular edema caused by central retinal vein occlusion. International Journal of Ophthalmology 2011 4 1 89 94
62. Singer M. A., Bell D. J., Woods P., Pollard J., Boord T., Herro A., Porbandarwalla S., Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion. Retina 2012 32 7 1289 1294 10.1097/IAE.0b013e318242b838